The meddling microbes midst our medicines - PubMed (original) (raw)
Editorial
. 2013 Sep-Oct;4(5):359-60.
doi: 10.4161/gmic.26250. Epub 2013 Aug 22.
Affiliations
- PMID: 23969979
- PMCID: PMC3839979
- DOI: 10.4161/gmic.26250
Editorial
The meddling microbes midst our medicines
Vk Viswanathan. Gut Microbes. 2013 Sep-Oct.
Abstract
It is not surprising that the complex metabolic machinery of the gut microbiome has accidental, or directed, ability to alter our medicines and influence their efficacy. What is not known is the extent to which this has contributed to drug failures or contraindications, or to the derailment of clinical trials. Some studies are unraveling the mechanisms by which the microbiota alter specific drugs, such as digoxin, and contribute to variations in efficacies between patient populations. Microbiome profiling, therefore, may well become an inevitable arm of all clinical trials in the future.
Keywords: Eggerthella lenta; digoxin; medicines; microbiota.
Figures
Figure 1. Digoxin is reduced to the cardioinactive dihydrodigoxin by E. lenta strains harboring the cgr operon. Digoxin induces cgr expression, and normal gut microbiota potentiate this induction; dietary protein, and arginine, inhibit cgr expression and digoxin reduction.
Similar articles
- Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics.
Haiser HJ, Seim KL, Balskus EP, Turnbaugh PJ. Haiser HJ, et al. Gut Microbes. 2014 Mar-Apr;5(2):233-8. doi: 10.4161/gmic.27915. Epub 2014 Jan 23. Gut Microbes. 2014. PMID: 24637603 Free PMC article. - Is it time for a metagenomic basis of therapeutics?
Haiser HJ, Turnbaugh PJ. Haiser HJ, et al. Science. 2012 Jun 8;336(6086):1253-5. doi: 10.1126/science.1224396. Epub 2012 Jun 6. Science. 2012. PMID: 22674325 - A review of metabolic potential of human gut microbiome in human nutrition.
Yadav M, Verma MK, Chauhan NS. Yadav M, et al. Arch Microbiol. 2018 Mar;200(2):203-217. doi: 10.1007/s00203-017-1459-x. Epub 2017 Nov 29. Arch Microbiol. 2018. PMID: 29188341 Review. - The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues.
Currò D. Currò D. Expert Rev Clin Pharmacol. 2018 Feb;11(2):171-183. doi: 10.1080/17512433.2018.1414598. Epub 2017 Dec 16. Expert Rev Clin Pharmacol. 2018. PMID: 29210311 Review. - Harnessing the Microbiome to Improve Drug Therapy.
Kelly L. Kelly L. Clin Pharmacol Ther. 2019 Aug;106(2):287-289. doi: 10.1002/cpt.1510. Clin Pharmacol Ther. 2019. PMID: 31355459 No abstract available.
Cited by
- Impact of Microbiota Transplant on Resistome of Gut Microbiota in Gnotobiotic Piglets and Human Subjects.
Liu H, Wang HH. Liu H, et al. Front Microbiol. 2020 May 19;11:932. doi: 10.3389/fmicb.2020.00932. eCollection 2020. Front Microbiol. 2020. PMID: 32508773 Free PMC article. - Inflammation and colorectal cancer, when microbiota-host mutualism breaks.
Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, Brigidi P. Candela M, et al. World J Gastroenterol. 2014 Jan 28;20(4):908-22. doi: 10.3748/wjg.v20.i4.908. World J Gastroenterol. 2014. PMID: 24574765 Free PMC article. Review.
References
- Leaf C. Do Clinical trials work? The New York Times (Online Ed.). 2013 July 13; http://www.nytimes.com/2013/07/14/opinion/sunday/do-clinical-trials-work...
- Herrmann I, Repke K. Transformation of cardenolides by microorganisms in the intestine. In: Schubert K, editor. Proceedings of the 2nd Symposium Über Biochemische Aspekte der Steroidforschung; 1968; Berlin, Germany. Berlin: Akademie-Verlag; 1969. p. 115–119.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical